International Cancer Conference Journal最新文献

{"title":"Coexisting germline variants of <i>MLH1</i> and <i>MSH6</i> in a patient with Lynch syndrome who had uterine and ovarian cancer.","authors":"Sho Umegaki, Masanobu Takahashi, Junko Hasegawa-Minato, Maako Kawamura, Sakura Taniguchi, Keigo Komine, Hideki Tokunaga, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota, Fumiyoshi Fujishima, Muneaki Shimada, Yoko Aoki, Chikashi Ishioka","doi":"10.1007/s13691-025-00753-2","DOIUrl":"10.1007/s13691-025-00753-2","url":null,"abstract":"<p><p>Lynch syndrome is an autosomal dominant disorder caused by a heterozygous pathogenic germline variant in mismatch repair (MMR) genes including <i>MLH1</i>, <i>MSH2</i>, <i>MSH6</i>, <i>PMS2</i>, and <i>EPCAM</i>. This disease often causes a familial cluster of patients with malignant tumors. In this report, we describe a 37-year-old woman who presented with endometrioid carcinoma in the ovary and uterine corpus associated with Lynch syndrome. She carried two germline pathogenic variants, a recurrently reported <i>MLH1</i> c.2250C > G (p.Tyr750*) and a previously unreported <i>MSH6</i> c.2385del (p.Ile795Metfs*15). The tumor cells showed microsatellite instability. Immunohistochemistry for the endometrial tumor showed decreased MLH1 expression, loss of PMS2 expression, retained MSH2 expression, and loss of MSH6 expression, which suggests that both variants impair each protein stability and thus cause MMR deficiency. Whether these variants were inherited from her parents or occurred de novo was unknown. The tumor cells had somatic variants <i>BRCA1</i> c.1016del and <i>BRCA2</i> c.36dupT that might be due to secondary mutation by MMR deficiency. The use of an immune checkpoint inhibitor pembrolizumab resulted in durable partial response of metastatic lung tumors. This case reminds clinicians of the rare possibility of multiple germline variants in MMR genes in individuals with Lynch syndrome.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"171-176"},"PeriodicalIF":0.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of triple-negative breast cancer with thalassemia manifested by anemia progression during neoadjuvant chemotherapy.","authors":"Yoshinobu Fuse, Atsushi Fushimi, Eijirou Nagasaki, Takashi Kazama, Eriko Taguchi, Makiko Kamio, Hisashi Shioya, Yasuo Toriumi, Hiroshi Takeyama, Hiroko Nogi","doi":"10.1007/s13691-025-00755-0","DOIUrl":"10.1007/s13691-025-00755-0","url":null,"abstract":"<p><p>Thalassemia is an inherited hemoglobinopathy characterized by anemia. In Japan, beta-thalassemia occurs in only 1 in 1000 individuals, and reports of thalassemia in patients with breast cancer are extremely rare. We report a case of triple-negative breast cancer in which thalassemia manifested as progressive anemia during neoadjuvant chemotherapy. A Filipino woman in her 40 s with a family history of breast cancer presented with a left breast mass. Physical examination revealed a 2-cm palpable mass in the outer lower quadrant of the left breast. Ultrasonography confirmed a 21-mm irregular hypoechoic mass in the corresponding area with immunohistochemistry indicating a triple-negative phenotype (ER-, PgR-, HER2-negative, Ki-67 index 60%). Pembrolizumab, paclitaxel, and carboplatin were administered every 3 weeks, during which the hemoglobin (Hb) level gradually decreased. Thalassemia was diagnosed based on low pretreatment mean corpuscular volume (67.6 fL), presence of target cells in peripheral blood, and elevated fetal hemoglobin (HbF) levels. Despite the anemia progression, the patient was able to complete the planned chemotherapy regimen with blood transfusion support. This included 4 cycles of pembrolizumab, doxorubicin, and cyclophosphamide. Subsequently, a partial mastectomy plus sentinel lymph node biopsy was performed, and the patient achieved a pathological complete response. This case demonstrates that neoadjuvant chemotherapy for breast cancer can be successfully completed with appropriate blood transfusion support in patients with thalassemia-induced anemia.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"185-188"},"PeriodicalIF":0.5,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950498/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-occurrence of breast cancer and malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1.","authors":"Nanami Sugimura, Shintaro Takao, Akiko Okamoto, Masaru Miyashita, Naoko Chayahara, Takuya Takahashi, Hiroaki Sanada, Naoki Kanata, Naoto Katayama","doi":"10.1007/s13691-025-00754-1","DOIUrl":"10.1007/s13691-025-00754-1","url":null,"abstract":"<p><p>Patients with neurofibromatosis type 1 (NF1) have an increased risk of developing breast cancer and other malignancies. During the search for breast cancer metastases in NF1 patients, there is a substantial probability of detecting malignancies other than breast cancer. We present a case of an 80-year-old woman with NF1 who was diagnosed with both invasive ductal carcinoma of the luminal-HER2 type in the breast and a malignant peripheral nerve sheath tumor (MPNST) of the liver. After noticing a lump in her right breast for 2 months, further examination confirmed breast cancer with metastases to the right axillary lymph nodes. A whole-body contrast-enhanced CT scan revealed large hepatic tumors initially suspected to be metastases from breast cancer. However, given the patient's underlying NF1, an ultrasound-guided liver biopsy was performed, which confirmed the diagnosis of MPNST. The patient had a history of surgical resection for the MPNST in the forearm. Due to the high metastatic potential of MPNST, the liver tumors were diagnosed as metastases of the MPNST. She declined chemotherapy for MPNST and is currently receiving endocrine therapy alone for breast cancer. It is necessary to acknowledge the predisposition of patients with NF1 to develop various tumors throughout the body. When performing a systemic evaluation for breast cancer in NF1 patients, any detected lesions should be thoroughly investigated for potential malignancies other than breast cancer metastasis. Biopsy and pathological examinations are useful to ensure an accurate differential diagnosis.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"177-184"},"PeriodicalIF":0.5,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of plasmablastic lymphoma and adenocarcinoma in the stomach: a case report and literature review.","authors":"Takato Maeda, Takenori Takahata, Shintaro Goto, Takao Oyama, Satoru Nakagawa, Yasuhisa Murai, Ryuma Machida, Nao Ishidoya, Juichi Sakamoto, Hideki Iwamura, Hirotake Sakuraba","doi":"10.1007/s13691-025-00751-4","DOIUrl":"10.1007/s13691-025-00751-4","url":null,"abstract":"<p><p>Plasmablastic lymphoma (PBL) is a rare B-cell lymphoma. Reports on primary gastric PBL are limited, and its endoscopic features remain poorly understood. We report a case of gastric PBL with multiple polypoid lesions in an immunocompetent individual. A 72-year-old man presented with upper abdominal discomfort. Esophagogastroduodenoscopy (EGD) revealed multiple raised lesions of variable sizes in the stomach, prompting a tumor biopsy. Based on histopathological findings, diffuse large B-cell lymphoma was suspected. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy was administered. After six cycles of R-CHOP therapy, EGD showed a partial reduction of the gastric tumor, and a biopsy was performed on the remaining tumor. Histopathology was re-examined, and immunohistochemical analysis revealed that the tumor cells were plasmablastic and strongly positive for both CD38 and CD138. The cells showed cytoplasmic immunoglobulin lambda light-chain restriction, indicating PBL. Furthermore, gastric differentiated adenocarcinoma was incidentally detected in some biopsy samples. Finally, a total gastrectomy was performed, and the postoperative course was uneventful. The patient is currently alive, 15 months after the initial diagnosis. This case reveals an endoscopic feature of gastric PBL and suggests the rare possibility that gastric PBL may coexist with adenocarcinoma.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-025-00751-4.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"155-162"},"PeriodicalIF":0.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitor restores daily function in patient with microsatellite instability (MSI)-high advanced endometrial cancer and poor performance status.","authors":"Ayaka Matsui, Taichi Yoshida, Yuya Takahashi, Koji Fukuda, Kazuhiro Shimazu, Daiki Taguchi, Hanae Shinozaki, Naoaki Kodama, Shunsuke Kato, Hironori Waki, Hiroshi Nanjo, Hiroyuki Shibata","doi":"10.1007/s13691-025-00752-3","DOIUrl":"10.1007/s13691-025-00752-3","url":null,"abstract":"<p><p>The immune checkpoint system suppresses T-cell activity. Unlike cytotoxic anticancer drugs that directly kill cells, immune checkpoint inhibitors (ICIs) are generally safer by stimulating tumor immunity. However, most clinical trials require patients to have a better performance status (PS), leaving limited evidence for those with poorer PS. In practice, patients may be classified with poor PS due to tumor-induced pain and motor dysfunction, even if major organs remain functional. Real-world data on non-small cell lung cancer has shown no safety difference between patients with PS 3/4 and those with lower PS. Approximately 20-30% of endometrial cancer cases show microsatellite instability-high (MSI-high), the highest among common malignancies. A 46-year-old patient with advanced, recurrent endometrial cancer resistant to standard chemotherapy, and PS of 4 from severe pelvic pain, was diagnosed with MSI-high. Pembrolizumab was initiated and continued for 19 courses, after which lesions had disappeared or calcified, leading to drug discontinuation. Now, 4 and a half years post-treatment, she has regained independent mobility and returned to work, and her PS has improved to approximately 1. Side effects included Grade 2 or lower thyroiditis, hypothyroidism, and hypoadrenalism, manageable with hormone replacement therapy and temporary pembrolizumab suspension. This case underscores the need to test for MSI-high/mismatch repair deficiency in endometrial cancer and to consider ICI therapy in patients with poor PS but no major organ dysfunction. In such cases, ICI can rapidly improve overall condition, a phenomenon known as a Lazarus-type response, as seen in other cancers such as non-small cell lung cancer.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-025-00752-3.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"163-170"},"PeriodicalIF":0.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional response to brigatinib following alectinib failure in a patient with <i>ALK</i> fusion-positive duodenal carcinoma.","authors":"Akinori Sasaki, Sayaka Chihara, Risa Okamoto, Takayuki Yoshino, Yoshiaki Nakamura","doi":"10.1007/s13691-025-00745-2","DOIUrl":"10.1007/s13691-025-00745-2","url":null,"abstract":"<p><p>Patients with advanced duodenal carcinoma typically have a poor prognosis due to limited practical chemotherapy options. While studies on genotype-directed therapy in patients with duodenal carcinoma is progressing, clinical data assessing the efficacy of molecularly targeted therapy remains scarce. We report the case of a 65-year-old woman diagnosed with anaplastic lymphocyte kinase (<i>ALK</i>) fusion-positive advanced duodenal carcinoma. The patient had been treated with alectinib for approximately 2 years for <i>ALK</i>-positive duodenal carcinoma but developed progressive liver metastases, indicating alectinib failure. During the disease progression, circulating tumor DNA (ctDNA) sequencing revealed the emergence of <i>ALK</i> L1196M mutation, which demonstrated sensitivity to brigatinib. After switching to brigatinib, marked shrinkage of liver metastases was observed. The patient maintained brigatinib treatment for 7 months until tumor progression. This is the first report demonstrating the efficacy of brigatinib after alectinib failure in a patient with duodenal carcinoma harboring <i>ALK</i> fusion. Furthermore, this case suggests that ctDNA sequencing can detect specific acquired mutations and help expand optimal treatment options for patients.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"131-135"},"PeriodicalIF":0.5,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950605/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopically resected appendiceal dual tumor composed of goblet cell carcinoma and low-grade mucinous neoplasm: a case report and literature review.","authors":"Kosuke Hirose, Kazuhito Minami, Yumi Oshiro, Daisuke Taniguchi, Yuichiro Kajiwara, Yasuo Tsuda, Hajime Otsu, Yusuke Yonemura, Koshi Mimori","doi":"10.1007/s13691-025-00748-z","DOIUrl":"10.1007/s13691-025-00748-z","url":null,"abstract":"<p><p>Dual tumors, comprising two different types of tumor, are uncommon pathologic findings. Appendiceal goblet cell carcinoid is an unusual and unique subtype of primary appendiceal neuroendocrine tumor defined by the World Health Organization, showing hybrid epithelial-neuroendocrine features. Low-grade mucinous neoplasms are also rare appendiceal neoplasms. However, the relationship between these two types of tumors is not well known. We present the case of a 46-year-old woman with a 5 cm appendiceal cystic tumor that was incidentally detected on abdominal computed tomography. She showed no abdominal symptoms, enlarged lymph nodes, or obvious distant metastases. Laparoscopic ileocecal resection was performed without complications or tumor injury. No disseminated lesions or mucus accumulation was found in the abdominal cavity during the operation. Pathologic examination revealed low-grade mucinous tumor cells lining the cystic mucosal cavity and a chromogranin A-positive goblet cell carcinoid near the mucinous cell components. As there was no mixture of the two cell types, the tumor was suspected of a collision tumor. Although reports on appendiceal collision tumors are limited, these two tumor types might arise from different types of progenitor cells. Furthermore, the laparoscopic approach, which allows for a more detailed and safer observation of the entire abdominal cavity, could be useful for accurate staging and treatment decisions in mucinous appendiceal tumors at risk of intraperitoneal mucinous dissemination and peritoneal pseudomyxoma. Accumulation of case reports of such dual tumors and analysis at the molecular and cellular level are necessary to elucidate their pathogenesis and development.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"136-142"},"PeriodicalIF":0.5,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastrectomy after neoadjuvant chemotherapy in five cases of locally advanced gastric cancer with pancreatic head invasion.","authors":"Mikihiro Kano, Noriaki Tokumoto, Kazuaki Tanabe, Jun Hihara, Kazuhiro Toyota, Ryuichi Hotta, Yoshihiro Saeki, Hirofumi Tazawa, Nobuaki Fujikuni","doi":"10.1007/s13691-025-00750-5","DOIUrl":"10.1007/s13691-025-00750-5","url":null,"abstract":"<p><p>Locally advanced gastric cancer (LAGC) with pancreatic head invasion (T4b) carries a poor prognosis despite radical surgery. Herein, we report the effectiveness of neoadjuvant chemotherapy (NAC) in improving the resectability of advanced gastric cancer with pancreatic invasion. A total of 2191 cases of gastric cancer were retrospectively analyzed from 13 institutions within the Hiroshima Surgical Study Group of Clinical Oncology (Hisco) database from 2018 to 2020. Among them, 5 of the 24 patients with Stage cT4b gastric cancer underwent NAC for three-to-eight cycles. Following chemotherapy, three patients underwent total gastrectomy, two patients underwent distal gastrectomy, and no patient underwent pancreaticoduodenectomy (PD). All five patients achieved a chemotherapeutic response of Grade 1b or higher, and only one case showed residual pancreatic invasion on pathology. This study suggests that NAC for Stage T4b LAGC with pancreatic head invasion may have the potential to obviate the need for PD.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"147-154"},"PeriodicalIF":0.5,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary adenocarcinoma of the lacrimal sac with 5-year recurrence-free survival after radiation therapy alone: a case report.","authors":"Daichi Takizawa, Kayoko Ohnishi, Kentaro Hiratsuka, Ryota Matsuoka, Keiichiro Baba, Masatoshi Nakamura, Takashi Iizumi, Kiyotaka Suzuki, Masashi Mizumoto, Hideyuki Sakurai","doi":"10.1007/s13691-025-00747-0","DOIUrl":"10.1007/s13691-025-00747-0","url":null,"abstract":"<p><p>Lacrimal sac tumors are rare, with approximately 800 cases reported worldwide; primary adenocarcinoma of the lacrimal sac is particularly rare. Although there is no established treatment strategy, surgical removal is generally performed. However, complete removal often requires extensive resection, including orbital exenteration and lateral rhinoplasty, which is highly invasive and creates significant cosmetic issues. Here, we report our experience with a 72-year-old woman with primary adenocarcinoma of the lacrimal sac with ethmoid bone invasion. She refused surgery and was treated with radiation therapy alone, totaling 70 Gy in 35 fractions. This is the first report of a patient with primary adenocarcinoma of the lacrimal sac who survived for 5 years without recurrence after radiation therapy alone. She experienced late radiation-related complications: the affected eye developed grade-3 retinopathy according to the common terminology criteria for adverse events, version 5.0, and secondary neovascular glaucoma. Cataract and vitreous surgery with retinal photocoagulation were performed. Her cosmetic appearance was maintained after all treatments were completed. Radiation therapy may be an effective treatment for primary adenocarcinoma of the lacrimal sac for patients who either refuse surgery or in whom surgery is not feasible.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"124-130"},"PeriodicalIF":0.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cisplatin-induced therapy-related myelodysplastic syndrome during avelumab maintenance therapy for metastatic urothelial carcinoma.","authors":"Yusuke Sugino, Taketomo Nishikawa, Sota Inaba, Shunsuke Owa, Momoko Kato, Shinichiro Higashi, Takeshi Sasaki, Satoru Masui, Kouhei Nishikawa, Akihide Nakamura, Miki Usui, Takahiro Inoue","doi":"10.1007/s13691-024-00735-w","DOIUrl":"10.1007/s13691-024-00735-w","url":null,"abstract":"<p><p>A 64 year-old man underwent a radical cystectomy for muscle-invasive bladder cancer. Five years later, lung and mediastinal lymph node metastases were detected. After 15 courses of gemcitabine and cisplatin for metastatic urothelial carcinoma, the patient was switched to avelumab maintenance therapy. During this period, the patient developed a therapy-related myelodysplastic syndrome, leading to difficulty in continuing treatment. Therapy-related myelodysplastic syndrome is a dose-dependent complication that can develop several years after chemotherapy or radiotherapy. Therefore, excessive cisplatin administration should be avoided.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 2","pages":"73-78"},"PeriodicalIF":0.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}